Effects of Cognitive Therapy for Depression on Insomnia in Women with Metastatic Breast Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: a clinical level of insomnia (PRE = 77
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Although insomnia improved over time, 21.0% to 46.3% of women reported residual insomnia symptoms following CT for depression. Therefore, a concomitant treatment that directly targets insomnia should be provided to women with cooccurring depression and insomnia.
[OBJECTIVE] This study assessed the effects of cognitive therapy (CT) for depression on insomnia in women with metastatic breast cancer.
APA
Mc Brearty C, Savard J (2026). Effects of Cognitive Therapy for Depression on Insomnia in Women with Metastatic Breast Cancer.. Behavioral sleep medicine, 24(1), 15-28. https://doi.org/10.1080/15402002.2025.2549550
MLA
Mc Brearty C, et al.. "Effects of Cognitive Therapy for Depression on Insomnia in Women with Metastatic Breast Cancer.." Behavioral sleep medicine, vol. 24, no. 1, 2026, pp. 15-28.
PMID
40891994 ↗
Abstract 한글 요약
[OBJECTIVE] This study assessed the effects of cognitive therapy (CT) for depression on insomnia in women with metastatic breast cancer.
[METHODS] Thirty-four women with metastatic breast cancer and depressive symptoms were randomly assigned to CT for depression or a waitlist control group (WLC). Insomnia was measured using the Insomnia Severity Index (ISI) at pre-treatment (PRE) and posttreatment (POST), as well as 3 (FU3) and 6 (FU6) months later.
[RESULTS] In the CT group, the proportion of women obtaining a clinically significant level of insomnia (ISI ≥8) decreased significantly from pre- to posttreatment (PRE = 80.0%; POST = 26.7%; = .013). The mean ISI score differed significantly between groups at posttreatment/waiting (intervention = 5.5; control = 12.7; = .048) and the ISI score decreased significantly from pre- to posttreatment (PRE = 11.5; POST = 5.5; = .001). Additional analyses were performed pooling both groups together after WLC patients received CT. The proportion of patients with a clinical level of insomnia (PRE = 77.5%; POST = 28.3%; FU3 = 46.3%; FU6 = 21.0%; < .0001), and the mean ISI score significantly decreased over time(PRE = 12.1; POST = 5.0; FU3 = 8.0; FU6 = 5.5; < .0001).
[CONCLUSIONS] Although insomnia improved over time, 21.0% to 46.3% of women reported residual insomnia symptoms following CT for depression. Therefore, a concomitant treatment that directly targets insomnia should be provided to women with cooccurring depression and insomnia.
[METHODS] Thirty-four women with metastatic breast cancer and depressive symptoms were randomly assigned to CT for depression or a waitlist control group (WLC). Insomnia was measured using the Insomnia Severity Index (ISI) at pre-treatment (PRE) and posttreatment (POST), as well as 3 (FU3) and 6 (FU6) months later.
[RESULTS] In the CT group, the proportion of women obtaining a clinically significant level of insomnia (ISI ≥8) decreased significantly from pre- to posttreatment (PRE = 80.0%; POST = 26.7%; = .013). The mean ISI score differed significantly between groups at posttreatment/waiting (intervention = 5.5; control = 12.7; = .048) and the ISI score decreased significantly from pre- to posttreatment (PRE = 11.5; POST = 5.5; = .001). Additional analyses were performed pooling both groups together after WLC patients received CT. The proportion of patients with a clinical level of insomnia (PRE = 77.5%; POST = 28.3%; FU3 = 46.3%; FU6 = 21.0%; < .0001), and the mean ISI score significantly decreased over time(PRE = 12.1; POST = 5.0; FU3 = 8.0; FU6 = 5.5; < .0001).
[CONCLUSIONS] Although insomnia improved over time, 21.0% to 46.3% of women reported residual insomnia symptoms following CT for depression. Therefore, a concomitant treatment that directly targets insomnia should be provided to women with cooccurring depression and insomnia.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.